ES2044100T4 - Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos. - Google Patents

Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.

Info

Publication number
ES2044100T4
ES2044100T4 ES89304068T ES89304068T ES2044100T4 ES 2044100 T4 ES2044100 T4 ES 2044100T4 ES 89304068 T ES89304068 T ES 89304068T ES 89304068 T ES89304068 T ES 89304068T ES 2044100 T4 ES2044100 T4 ES 2044100T4
Authority
ES
Spain
Prior art keywords
paf
methods
antihistaminics
antagonists
certain combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89304068T
Other languages
English (en)
Other versions
ES2044100T3 (es
Inventor
Motasim M Billah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ES2044100T3 publication Critical patent/ES2044100T3/es
Application granted granted Critical
Publication of ES2044100T4 publication Critical patent/ES2044100T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES89304068T 1988-04-27 1989-04-24 Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos. Expired - Lifetime ES2044100T4 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18653588A 1988-04-27 1988-04-27

Publications (2)

Publication Number Publication Date
ES2044100T3 ES2044100T3 (es) 1994-01-01
ES2044100T4 true ES2044100T4 (es) 1996-07-16

Family

ID=22685331

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89304068T Expired - Lifetime ES2044100T4 (es) 1988-04-27 1989-04-24 Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.

Country Status (15)

Country Link
EP (2) EP0402422A1 (es)
JP (1) JPH0655673B2 (es)
KR (1) KR930009786B1 (es)
AT (1) ATE84724T1 (es)
AU (1) AU619555B2 (es)
CA (1) CA1327316C (es)
DE (1) DE68904475T2 (es)
DK (1) DK255190D0 (es)
ES (1) ES2044100T4 (es)
IE (1) IE63697B1 (es)
IL (1) IL90100A (es)
MY (1) MY106956A (es)
NZ (1) NZ228879A (es)
WO (1) WO1989010143A1 (es)
ZA (1) ZA893101B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US6277846B1 (en) * 1990-05-31 2001-08-21 Allergan Sales, Inc. Use of platelet activating factor antagonists as anti-pruritic agents
EP0469477B1 (en) * 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5227378A (en) * 1990-08-02 1993-07-13 Hoffmann-La Roche Inc. Combination of PAF antagonists and LTD4 antagonists for the treatment of allergic reactions
FR2673842B1 (fr) * 1991-03-13 1993-12-24 Rhone Poulenc Rorer Sa Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4.
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
JP3060287B2 (ja) * 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539332A (en) * 1983-11-14 1985-09-03 Merck & Co., Inc. 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
NZ211146A (en) * 1984-02-29 1987-10-30 Merck & Co Inc 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
US4595693A (en) * 1984-06-04 1986-06-17 Merck & Co., Inc. Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
DE3502392A1 (de) * 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
US4910206A (en) * 1986-07-14 1990-03-20 Sandoz Pharmaceuticals Corp. 5-hetero-or aryl-substituted-imidazo(2,1-a)isoquinolines and their use as PAF receptor antagonists

Also Published As

Publication number Publication date
EP0402422A1 (en) 1990-12-19
JPH03502097A (ja) 1991-05-16
MY106956A (en) 1995-08-30
KR900700136A (ko) 1990-08-11
DE68904475T2 (de) 1993-05-13
DE68904475D1 (de) 1993-03-04
NZ228879A (en) 1992-08-26
EP0345931A1 (en) 1989-12-13
WO1989010143A1 (en) 1989-11-02
IL90100A (en) 1995-01-24
IE891362L (en) 1989-10-27
CA1327316C (en) 1994-03-01
EP0345931B1 (en) 1993-01-20
IL90100A0 (en) 1989-12-15
ZA893101B (en) 1989-12-27
IE63697B1 (en) 1995-05-31
JPH0655673B2 (ja) 1994-07-27
DK255190A (da) 1990-10-23
ATE84724T1 (de) 1993-02-15
ES2044100T3 (es) 1994-01-01
AU3578289A (en) 1989-11-24
DK255190D0 (da) 1990-10-23
AU619555B2 (en) 1992-01-30
KR930009786B1 (ko) 1993-10-11

Similar Documents

Publication Publication Date Title
DE3884453D1 (de) Homogene additionscopolymere von ethylen und cycloolefinmonomeren und deren herstellung.
DE3853340D1 (de) Dien-Blockpolymer und Polymerzusammensetzung.
DE3871751T2 (de) Gelbildende organosiloxanzusammensetzungen und deren verwendung.
DE3873616D1 (de) Polyacetal-harzzusammensetzung und daraus hergestellte gleitteile.
DE69116705D1 (de) Antiglancoma-Zusammensetzungen enthaltend 3-Arylcarbonyl-1-aminoalkyl-1H-indol
DE68906345T2 (de) Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten.
ATE131056T1 (de) Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen.
DE384953T1 (de) Huepfspiel und dessen spielart.
ES2044100T4 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
IT1212143B (it) Composizione ad attivita'tricogena.
DE69002520D1 (de) Azeotropaehnliche zusammensetzungen von 1,1-dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1-fluoraethan.
NO830527L (no) Analogifremgangsmaate for fremstilling av 2,3-diaryl-5-halogenthiofener
DE68914711D1 (de) 1,4-Disubstituierte-2,3,4,6-tetrahydroxy-1,4-diphosphorinan und ihre Oxide oder Sulfides.
DE69015411T2 (de) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
DE68919593D1 (de) Verwendung von Zofenopril zur Herstellung von Medikamenten gegen rheumatoide Arthritis.
DE69004897D1 (de) Zusammensetzungen von Polyimidvorläufern und ihre Verwendungen.
ATE80873T1 (de) Tetrahydropyridin-derivate.
DE3884407D1 (de) Trifluormethyl-1-tetralinabkömmlinge, deren herstellung und verwendung bei der herstellung von verbindungen mit therapeutischer wirkung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 345931

Country of ref document: ES

FG2A Definitive protection

Ref document number: 0345931

Country of ref document: ES